Siren L.L.C. Invests $16.35 Million in uniQure N.V. $QURE

Siren L.L.C. acquired a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,000,000 shares of the biotechnology company’s stock, valued at approximately $16,350,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Woodline Partners LP increased its stake in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares in the last quarter. Legal & General Group Plc bought a new stake in uniQure during the second quarter valued at about $497,000. Marshall Wace LLP raised its holdings in uniQure by 276.5% during the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares during the period. California State Teachers Retirement System purchased a new position in shares of uniQure in the second quarter valued at about $540,000. Finally, Ameriprise Financial Inc. lifted its position in shares of uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after acquiring an additional 212,218 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 21,167 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the transaction, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director owned 43,254 shares of the company’s stock, valued at $1,949,025.24. This represents a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 433,229 shares of company stock valued at $17,944,799 in the last 90 days. 4.65% of the stock is currently owned by insiders.

uniQure Stock Down 2.4%

Shares of QURE stock opened at $39.43 on Friday. The company’s fifty day simple moving average is $35.70 and its two-hundred day simple moving average is $25.57. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The stock has a market cap of $2.49 billion, a P/E ratio of -11.33 and a beta of 0.90. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Analysts predict that uniQure N.V. will post -3.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on QURE shares. Chardan Capital increased their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Stifel Nicolaus set a $28.00 target price on uniQure in a research note on Tuesday, May 5th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a report on Wednesday, June 17th. The Goldman Sachs Group upped their price target on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research note on Thursday, June 18th. Finally, Barclays raised shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $25.00 to $65.00 in a report on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $64.17.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.